Evolutionary and immunological implications of contemporary HIV-1 variation

British Medical Bulletin

Volumn 58, Issue , 2001, Pages 19-42

  Korber, Bette ^a,b,c   Gaschen, Brian ^a   Yusim, Karina ^a,b,c   Thakallapally, Rama ^a   Kesmir, Can ^b,c   Detours, Vincent ^a,b,c  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b SANTA FE INSTITUTE   (United States)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ENVELOPE PROTEIN;

CLUSTER ANALYSIS; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOLOGY; MOLECULAR EVOLUTION; PHYLOGENY; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE;

AIDS VACCINES; ANIMALS; ANTIGENIC VARIATION; CROSS REACTIONS; DRUG DESIGN; EPITOPE MAPPING; EPITOPES; EVOLUTION, MOLECULAR; HAEMOPHILUS VACCINES; HIV-1; HUMANS; INFLUENZA A VIRUS; MUTATION; PHYLOGENY; T-LYMPHOCYTES, CYTOTOXIC; VARIATION (GENETICS); WORLD HEALTH;

EID: 0035162494     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/58.1.19     Document Type: Review

References (131)

1. Methods of detection of HIV-specific CTL and their role in protection against HIV infection
2. Rates of spontaneous mutation among RNA viruses
3. Evolutionary dynamics of HTLV-I
4. Decay characteristics of HIV-1-infected compartments during combination therapy
5. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection
6. Adaptive evolution of human immunodeficiency virus type 1 during the natural course of infection
7. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
8. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period
9. On the nature of virus quasispecies
10. Resistance to HIV protease inhibitors
11. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
12. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
13. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
14. Timing the ancestor of the HIV-1 pandemic strains
15. A combinatorial ledge: Reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance
16. Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression
17. HLA class I homozygosity accelerates disease progression in human
18. Anti-viral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
19. Patterns of immunodominance in HW-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation
20. Are RNA viruses adapting or merely changing?
21. Codon-substitution models for heterogeneous selection pressure at amino acid sites
22. Evolution of pathogenic viruses with special reference to the rates of synonymous and non-synonymous substitutions
23. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1
24. HIV signature and sequence variation analysis
25. Re-evaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes
26. Genealogical evidence for positive selection in the nef gene of HIV-1
27. Inter- and intra-subtype neutralization of human immunodeficiency virus type 1: The genetic subtypes do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes
28. Multivariate analysis of human immunodeficiency virus type 1 neutralization data
29. Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase
30. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa
31. CTL cross-reactivity among different HW-1 clades: Implications for vaccine development
32. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients
33. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
34. Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children
35. Diversity and evolution of primate lentiviruses
36. AIDS as a zoonosis: Scientific and public health implications
37. Genetic characterization of new West African simian immunodeficiency virus SIVsm: Geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop
38. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys
39. Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon
40. Origin of HIV-1 in the chimpanzee Pan troglodytes
41. Serological and virological characterization of HIV-1 group O infection in Cameroon
42. Geographical distribution of HIV-1 group O viruses in Africa
43. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
44. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic
45. Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes by using a new method to uncover clock-like molecular evolution
46. Origins and evolution of AIDS viruses: Estimating the rime-scale
47. Application of molecular systematics: The state of the field and a look to the future
48. Limitations of a molecular clock applied to considerations of the origins of HIV-1
49. Population dynamics of HIV-1 inferred from gene sequences
50. Coalescent estimates of HIV-1 generation time in vivo
51. An integrated framework for the inference of viral population history from reconstructed genealogies
52. Using HIV-1 sequences to infer historical features of the AIDS epidemic and HIV evolution
53. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa
54. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes
55. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1
56. HIV-1 subtypes: Implications for epidemiology, pathogenicity, vaccines and diagnostics
57. HIV-1 nomenclature proposal
58. HIV-1 nomenclature proposal
59. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin
60. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand
61. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria
62. Spread of distinct human immunodeficiency virus type 1 AG recombinant lineages in Africa
63. Characterization of subtype A HIV-1 from Africa by full genome sequencing
64. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China
65. HIV-1 genetic subtype A/B recombinant strain causing an explosive epidemic in injecting drug users in Kaliningrad
66. HIV-1 sequence alignments
67. Molecular cloning and characterization of the HTLV-III virus associated with AIDS
68. A role for carbohydrates in immune evasion in AIDS
69. Maximum likelihood phylogenetic estimation from DNA sequences with variable rates over sites: Approximate methods
70. Genes and proteins of the influenza viruses
71. A review of avian influenza in different bird species
72. Variation in influenza virus genes
73. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness
74. Discovery of men infected by avian influenza A (H9N2) virus
75. Human infection with influenza H9N2
76. Recent human influenza A (H1N1) viruses are closely related genetically to strains isolated in 1950
77. Antigenic similarity of influenza A (H1N1) viruses from epidemics in 1977-1978 to 'Scandinavian' strains isolated in epidemics of 1950-1951
78. Influenza
79. Update: Influenza activity - United States and worldwide, 1999-2000 season, and composition of the 2000-01 influenza vaccine
80. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
81. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
82. A recombinant human immunodeficiency virus type I envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
83. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type I virions of group M
84. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
85. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination
86. + T cell responses to Env
87. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
88. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: Soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120
89. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades
90. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons
91. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects
92. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women
93. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
94. Broadly cross-reactive HIV-specific cyroroxic T-lymphocytes in highly-exposed persistently seronegative donors
95. Long-term non-progressive infection with human immunodeficiency virus type 1 in a hemophilia cohort
96. HIV type 1-specific helper T cells: A critical host defense
97. Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SW
98. Influence of combinations of MHC genes on the course of HiV-1 infection
99. Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules
100. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
101. Crossreactive HIV-1-specific CTL in recent seroconverters from Pune, India
102. Cross-clade T cell recognition of HIV-1
103. Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission
104. Human immunodeficiency virus type 1 Rev-and Tat-specific cyrotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
105. CTL epitopes
106. Course of specific T lymphocyte cytotoxicity, plasma and cellular viral loads, and neutralizing antibody titers in 17 recently seroconverted HIV type 1-infected patients
107. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS
108. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines
109. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and Caucasoid adults and children
110. HIV-1 DNA vaccines
111. Correlates of protection, antigen delivery and molecular epidemiology: Basics for designing an HIV vaccine
112. + cytotoxic T lymphocyte responses in seronegative volunteers
113. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces non-infectious virus particles
114. Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity, by a peptide vaccine candidate
115. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine
116. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
117. Evolution of the human immunodeficiency virus type 1 subtype-specific V3 domain is confined to a sequence space with a fixed distance to the subtype consensus
118. Epidemiological and immunological implications of the global variability of HIV-1
119. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex
120. Mechanisms of MHC class I-restricted antigen processing
121. Function of the transport complex TAP in cellular immune recognition
122. Limited diversity of peptides related to an alloreactive T cell epitope in the HLA-B27-bound peptide repertoire results from restrictions at multiple steps along the processing-loading pathway
123. Abrogation of CTL epitope processing by single amino acid substitution flanking the C-terminal proteasome cleavage site
124. Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects
125. The specificity of proteasomes: Impact on MHC class I processing and presentation of antigens
126. A giant protease with potential to substitute for some functions of the proteasome
127. Two new proteases in the MHC class I processing pathway
128. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules